The U.S. Federal Trade Commission found only one antitrust wrinkle in the combo of the consumer health units of GlaxoSmithKline and Novartis and says it has been ironed out. Novartis will sell its Habitrol nicotine patch business so the new joint venture will not have too much market sway in pricing of nicotine patches in the U.S.
Italy's drug regulator has a growing investigation on its hands, and Novartis is in the middle of it. The number of people who have died in the country after receiving one of the Swiss pharma giant's flu vaccines has risen by 10 just days after Italy issued a partial ban on the product.
In biotech, here are the top 10 news stories of the year so far, based on web traffic.
Novartis has washed its hands of a researcher who admitted to falsifying results in a series of published papers, promising to dig into his work at the company to determine whether the pattern continued in its own labs.
The FDA wants more time to deliberate on Novartis' panobinostat, a multiple myeloma treatment that failed to impress a panel of independent experts, signaling a delay that could nearly negate the agency's previous promise of a speedy review.
Glaxo shareholders will soon have the chance to weigh in on an asset swap between GlaxoSmithKline and Novartis worth more than $20 billion.
Novartis is well on its way to leading a new class of anti-inflammatory treatments, convincing European regulators to recommend approving its injected therapy for psoriasis and putting the company in line for transatlantic launches next year.
BioNano Genomics has restocked its coffers to fund an assault on the genome analysis sector. The San Diego, CA-based genome mapping firm raised a $53 million war chest from Novartis' venture fund and other investors to accelerate uptake of its Irys DNA analysis device and accompanying software.
The U.K. and Novartis have been negotiating for months now on a fair price for the Swiss pharma's meningitis B shot, Bexsero, which the country plans to add to its childhood vaccination schedule. So what's the holdup?
Earlier this month, U.K. politicians asked Prime Minister David Cameron to explain why Novartis' Bexsero, approved as an addition to the country's childhood immunization schedule 8 months back, had yet to be covered by the National Health Service. Now, Cameron has asked Health Secretary Jeremy Hunt to do the same--and Hunt is pointing the finger at the Swiss pharma.